Evidence map›Paper›PMID 33051659›Full record

ArticleThe Journal of clinical endocrinology and metabolism2021

Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update.

Gustavo Armaiz-Pena, Shahida K Flores, Zi-Ming Cheng, Xhingyu Zhang, Emmanuel Esquivel, Natalie Poullard, Anusha Vaidyanathan, Qianqian Liu, Joel Michalek, Alfredo A Santillan-Gomez and 28 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Molecular Genetics of Pheochromocytoma/Paraganglioma.Current opinion in endocrine and metabolic research · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Update on the genetics of paragangliomas.Endocrine-related cancer · 2023
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 16 institutions in 5 countries.

Gustavo Armaiz-PenaDivision of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
Shahida K FloresDivision of Hematology and Medical Oncology, Department of Medicine, UTHSA, San Antonio, Texas.
Zi-Ming ChengDivision of Hematology and Medical Oncology, Department of Medicine, UTHSA, San Antonio, Texas.
Xhingyu ZhangDivision of Hematology and Medical Oncology, Department of Medicine, UTHSA, San Antonio, Texas.
Emmanuel EsquivelDivision of Hematology and Medical Oncology, Department of Medicine, UTHSA, San Antonio, Texas.
Natalie PoullardMays Cancer Center, UTHSA, San Antonio, Texas.
Anusha VaidyanathanMays Cancer Center, UTHSA, San Antonio, Texas.
Qianqian LiuDepartment of Population Health Sciences, UTHSA, San Antonio, Texas.
Joel MichalekDepartment of Population Health Sciences, UTHSA, San Antonio, Texas.
Alfredo A Santillan-GomezDivision of Surgical Oncology, Department of Surgery, UTHSA, San Antonio, Texas.
Michael LissDepartment of Urology, UTHSA, San Antonio, Texas.
Sara AhmadiDivision of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
Daniel KatselnikDiabetes and Metabolism Specialists, San Antonio, Texas, USA.
Enrique MaldonadoDivision of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
Sarimar Agosto SalgadoDepartment Endocrine Neoplasia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Camilo JimenezDepartment Endocrine Neoplasia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lauren FishbeinDivision of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Oksana HamidiDivision of Endocrinology and Metabolism, UT Southwestern Medical Center, Dallas, Texas.
Tobias ElseDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Ron LechanTufts Medical Center, Boston, Massachusetts.
Art S TischlerTufts Medical Center, Boston, Massachusetts.
Diana E BennCancer Genetics, Kolling Institute, Royal North Shore Hospital and University of Sydney, Sydney, NSW, Australia.
Trisha DwightCancer Genetics, Kolling Institute, Royal North Shore Hospital and University of Sydney, Sydney, NSW, Australia.
Rory Clifton-BlighCancer Genetics, Kolling Institute, Royal North Shore Hospital and University of Sydney, Sydney, NSW, Australia.
Gabriela SansoCenter for Endocrinological Investigations (CEDIE), Hospital de Niños R. Gutiérrez, Buenos Aires, C1425EFD Argentina.
Marta BarontiniCenter for Endocrinological Investigations (CEDIE), Hospital de Niños R. Gutiérrez, Buenos Aires, C1425EFD Argentina.
Deepa VincentDivision of Endocrinology, University of Massachusetts, Worcester, Massachusetts.
Neil AroninDivision of Endocrinology, University of Massachusetts, Worcester, Massachusetts.
Bernadette BiondiDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Maureen KoopsDivision of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
Elizabeth Bowhay-CarnesMays Cancer Center, UTHSA, San Antonio, Texas.
Anne-Paule Gimenez-RoqueploAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Genetics Department, Université de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
Andrea Alvarez-EslavaUniversity Health System, Texas Diabetes Institute, San Antonio, Texas.
Jan M BruderDivision of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
Mio KitanoMays Cancer Center, UTHSA, San Antonio, Texas.
Nelly BurnichonAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Genetics Department, Université de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
Yanli DingDepartment of Pathology, UTHSA, San Antonio, Texas.
Patricia L M DahiaDivision of Hematology and Medical Oncology, Department of Medicine, UTHSA, San Antonio, Texas.
The University of Texas Health Science Center at San Antonio · USMays Cancer Center at UT Health San AntonioThe University of Sydney · AUHospital General de Niños Ricardo Gutierrez · ARInserm · FRThe University of Texas MD Anderson Cancer Center · USTufts Medical Center · USUniversity of Massachusetts Chan Medical School · USAudie L. Murphy Memorial VA Hospital · USDiabetes & Endocrinology Specialists · USSouthwestern Medical Center · USUniversity Health System · USUniversity of Colorado Denver · USUniversity of Michigan · USUniversity of Naples Federico II · ITUrology San Antonio · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
Institute for Integration of Medicine & Science: A Partnership to Improve HealthUM1TR004538 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ROBERT A CLARK, Kenneth M Hargreaves · 2023 to 2026
$22.3M
Institute for Integration of Medicine & Science: A Partnership to Improve HealthUL1TR002645 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, HARGREAVES, KENNETH M · 2018 to 2022
$20.4M
Institute for Integration of Medicine & Science: A Partnership to Improve HealthUL1TR001120 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, HARGREAVES, KENNETH M · 2013 to 2017
$16.5M
Cancer Biology Training ProgramT32CA148724 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Pei Wang, Feng-Chun Yang · 2011 to 2026
$3.3M
Inherited genetic variation and penetrance of Hereditary Paraganglioma-Pheochromocytoma SyndromeR01CA246586 · NCI · UNIVERSITY OF COLORADO DENVER · PI FISHBEIN, LAUREN MICHELLE · 2020 to 2024
$1.8M
Interaction of the TMEM127 tumor suppressor with the mTORC1 lysosomal activating complexR01GM114102 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAHIA, PATRICIA LEAL · 2017 to 2021
$1.5M
Mechanisms of internalization and trafficking of the tumor suppressor and lysosomal membrane protein TMEM127F31GM131634 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FLORES, SHAHIDA KARINA · 2019 to 2019
$34k
NCATS NIH HHS UL1 TR001120NCATS NIH HHS UL1 TR002645NCATS NIH HHS UM1 TR004538NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA246586NCI NIH HHS T32 CA148724NIGMS NIH HHS F31 GM131634NIGMS NIH HHS R01 GM114102
6 · The paper itself

Abstract

purposeThis work aimed to evaluate genotype-phenotype associations in individuals carrying germline variants of transmembrane protein 127 gene (TMEM127), a poorly known gene that confers susceptibility to pheochromocytoma (PHEO) and paraganglioma (PGL).

designData were collected from a registry of probands with TMEM127 variants, published reports, and public databases. MAIN OUTCOME ANALYSIS: Clinical, genetic, and functional associations were determined.

resultsThe cohort comprised 110 index patients (111 variants) with a mean age of 45 years (range, 21-84 years). Females were predominant (76 vs 34, P < .001). Most patients had PHEO (n = 94; 85.5%), although PGL (n = 10; 9%) and renal cell carcinoma (RCC, n = 6; 5.4%) were also detected, either alone or in combination with PHEO. One-third of the cases had multiple tumors, and known family history was reported in 15.4%. Metastatic PHEO/PGL was rare (2.8%). Epinephrine alone, or combined with norepinephrine, accounted for 82% of the catecholamine profiles of PHEO/PGLs. Most variants (n = 63) occurred only once and 13 were recurrent (2-12 times). Although nontruncating variants were less frequent than truncating changes overall, they were predominant in non-PHEO clinical presentations (36% PHEO-only vs 69% other, P < .001) and clustered disproportionately within transmembrane regions (P < .01), underscoring the relevance of these domains for TMEM127 function. Integration of clinical and previous experimental data supported classification of variants into 4 groups based on mutation type, localization, and predicted disruption.

conclusionsPatients with TMEM127 variants often resemble sporadic nonmetastatic PHEOs. PGL and RCC may also co-occur, although their causal link requires further evaluation. We propose a new classification to predict variant pathogenicity and assist with carrier surveillance.

Indexed as

Adrenal Gland NeoplasmsAdultAgedAged, 80 and overCohort StudiesDatabases, GeneticFemaleGenetic Association StudiesGenetic Predisposition to DiseaseGenetic TestingGerm-Line MutationHumansMaleMembrane ProteinsMiddle AgedPheochromocytomaMembrane ProteinsTMEM127 protein, humangenotype-phenotype associationparagangliomapheochromocytomaTMEM127tumor suppressor gene

Identifiers

PMID33051659
PMCPMC7765648
OpenAlexW3091845247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.